SynAct Pharma AB

Stocks

SYNACT

SE0008241491

Market Closed - Nasdaq Stockholm 20:00:00 02/11/2026 +03			5-day change	1st Jan Change
16.14 ^SEK	-0.49%		-9.63%	-28.58%

05:03pm	Calendar Tuesday, November 3	FW
10-27	Synact Pharma enters commercial agreement with Brazilian company Hipolabor	FW

Transcript : SynAct Pharma AB - Special Call

Published on 06/15/2026 at 07:51 pm +03

S&P Capital IQ

Presenter Speech
Unknown Attendee (Attendees)

Here at Investor Studios, we are joined by SynAct Pharma, who today have announced the top line results for the Phase IIb ADVANCE study. And joining me

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about SynAct Pharma AB

05:03pm	Calendar Tuesday, November 3	FW
10-27	Synact Pharma enters commercial agreement with Brazilian company Hipolabor	FW
10-27	SynAct Pharma enters partnership agreement for resomelagon with Brazilian pharmaceutical company	FW
10-27	Synact Pharma Signs First Commercial Partnership for Resomelagon with Hipolabor Farmacêutica LTDA	CI
09-16	Synact Pharma's resomelagon highlighted by WHO for dengue fever	FW
09-16	SynAct Pharma Identifies Resomelagon As One Of Six Dengue Drug Candidates With Evidence Supporting Further Clinical Development	CI
09-07	Synact surged in Stockholm, the OMXS30 index rose 0.2 percent	FW
09-07	Rejlers slides on merger plans, OMXS30 index up 0.3 percent	FW
09-07	Synact Pharma sees support for phase 3 after post hoc analysis	FW
09-07	SynAct Pharma AB Announces Further Analysis Of Phase 2b ADVANCE Study And Supports Phase 3 Development For Resomelagon	CI
09-03	Stockholm stocks rise, Clas Ohlson jumps on earnings, OMXS30 index up 0.6 percent	FW
09-03	Synact Pharma CEO and head of research sell shares for tax reasons	FW
08-28	Synact Pharma to present new preclinical data for resomelagon at WCI	FW
08-28	SynAct Pharma Presents New Resomelagon Preclinical Data On Phase 3-Ready Ra Therapeutic Candidate At The 17th World Congress Of Inflammation 2026	CI
08-20	SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Chart SynAct Pharma AB

Duration

Period

SYNACT: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

Projected Income Statement - Annual - SynAct Pharma AB

More financial data

EPS Estimates

Evolution of Analysts' Estimates - EPS - SynAct Pharma AB

Revisions to estimates